{\rtf1\ansi\ansicpg1252\uc1 \deff0\deflang1033\deflangfe1033{\fonttbl{\f0\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}{\f28\fswiss\fcharset0\fprq2{\*\panose 020b0604030504040204}Verdana;} {\f31\froman\fcharset238\fprq2 Times New Roman CE;}{\f32\froman\fcharset204\fprq2 Times New Roman Cyr;}{\f34\froman\fcharset161\fprq2 Times New Roman Greek;}{\f35\froman\fcharset162\fprq2 Times New Roman Tur;} {\f36\froman\fcharset177\fprq2 Times New Roman (Hebrew);}{\f37\froman\fcharset178\fprq2 Times New Roman (Arabic);}{\f38\froman\fcharset186\fprq2 Times New Roman Baltic;}{\f255\fswiss\fcharset238\fprq2 Verdana CE;} {\f256\fswiss\fcharset204\fprq2 Verdana Cyr;}{\f258\fswiss\fcharset161\fprq2 Verdana Greek;}{\f259\fswiss\fcharset162\fprq2 Verdana Tur;}{\f262\fswiss\fcharset186\fprq2 Verdana Baltic;}}{\colortbl;\red0\green0\blue0;\red0\green0\blue255; \red0\green255\blue255;\red0\green255\blue0;\red255\green0\blue255;\red255\green0\blue0;\red255\green255\blue0;\red255\green255\blue255;\red0\green0\blue128;\red0\green128\blue128;\red0\green128\blue0;\red128\green0\blue128;\red128\green0\blue0; \red128\green128\blue0;\red128\green128\blue128;\red192\green192\blue192;}{\stylesheet{\ql \li0\ri0\widctlpar\faauto\adjustright\rin0\lin0\itap0 \fs20\lang2057\langfe1033\cgrid\langnp2057\langfenp1033 \snext0 Normal;}{ \s1\ql \li0\ri0\keepn\widctlpar\faauto\adjustright\rin0\lin0\itap0 \i\f28\fs20\lang2057\langfe1033\cgrid\langnp2057\langfenp1033 \sbasedon0 \snext0 heading 1;}{\s2\ql \li0\ri0\keepn\widctlpar\faauto\outlinelevel1\adjustright\rin0\lin0\itap0 \b\i\f28\fs17\lang2057\langfe1033\cgrid\langnp2057\langfenp1033 \sbasedon0 \snext0 heading 2;}{\*\cs10 \additive Default Paragraph Font;}{\s15\ql \li0\ri0\widctlpar\faauto\adjustright\rin0\lin0\itap0 \f28\fs17\lang2057\langfe1033\cgrid\langnp2057\langfenp1033 \sbasedon0 \snext15 Body Text;}}{\*\listtable{\list\listtemplateid-348096842{\listlevel\levelnfc0\levelnfcn0\leveljc0\leveljcn0\levelfollow0\levelstartat1\levelspace0\levelindent0{\leveltext \'02\'00.;}{\levelnumbers\'01;}\chbrdr\brdrnone\brdrcf1 \chshdng0\chcfpat1\chcbpat1 \fi-360\li720\jclisttab\tx720 }{\listlevel\levelnfc0\levelnfcn0\leveljc0\leveljcn0\levelfollow0\levelstartat1\levelspace0\levelindent0{\leveltext\'02\'01.;}{\levelnumbers \'01;}\chbrdr\brdrnone\brdrcf1 \chshdng0\chcfpat1\chcbpat1 \fi-360\li1440\jclisttab\tx1440 }{\listlevel\levelnfc0\levelnfcn0\leveljc0\leveljcn0\levelfollow0\levelstartat1\levelspace0\levelindent0{\leveltext\'02\'02.;}{\levelnumbers\'01;}\chbrdr \brdrnone\brdrcf1 \chshdng0\chcfpat1\chcbpat1 \fi-360\li2160\jclisttab\tx2160 }{\listlevel\levelnfc0\levelnfcn0\leveljc0\leveljcn0\levelfollow0\levelstartat1\levelspace0\levelindent0{\leveltext\'02\'03.;}{\levelnumbers\'01;}\chbrdr\brdrnone\brdrcf1 \chshdng0\chcfpat1\chcbpat1 \fi-360\li2880\jclisttab\tx2880 }{\listlevel\levelnfc0\levelnfcn0\leveljc0\leveljcn0\levelfollow0\levelstartat1\levelspace0\levelindent0{\leveltext\'02\'04.;}{\levelnumbers\'01;}\chbrdr\brdrnone\brdrcf1 \chshdng0\chcfpat1\chcbpat1 \fi-360\li3600\jclisttab\tx3600 }{\listlevel\levelnfc0\levelnfcn0\leveljc0\leveljcn0\levelfollow0\levelstartat1\levelspace0\levelindent0{\leveltext\'02\'05.;}{\levelnumbers\'01;}\chbrdr\brdrnone\brdrcf1 \chshdng0\chcfpat1\chcbpat1 \fi-360\li4320\jclisttab\tx4320 }{\listlevel\levelnfc0\levelnfcn0\leveljc0\leveljcn0\levelfollow0\levelstartat1\levelspace0\levelindent0{\leveltext\'02\'06.;}{\levelnumbers\'01;}\chbrdr\brdrnone\brdrcf1 \chshdng0\chcfpat1\chcbpat1 \fi-360\li5040\jclisttab\tx5040 }{\listlevel\levelnfc0\levelnfcn0\leveljc0\leveljcn0\levelfollow0\levelstartat1\levelspace0\levelindent0{\leveltext\'02\'07.;}{\levelnumbers\'01;}\chbrdr\brdrnone\brdrcf1 \chshdng0\chcfpat1\chcbpat1 \fi-360\li5760\jclisttab\tx5760 }{\listlevel\levelnfc0\levelnfcn0\leveljc0\leveljcn0\levelfollow0\levelstartat1\levelspace0\levelindent0{\leveltext\'02\'08.;}{\levelnumbers\'01;}\chbrdr\brdrnone\brdrcf1 \chshdng0\chcfpat1\chcbpat1 \fi-360\li6480\jclisttab\tx6480 }{\listname ;}\listid1172448137}}{\*\listoverridetable{\listoverride\listid1172448137\listoverridecount0\ls1}}{\info{\title Submitting an abstract for the PAGE meeting}{\author Rik Schoemaker} {\operator Rik Schoemaker}{\creatim\yr2005\mo3\dy9\hr21\min27}{\revtim\yr2007\mo1\dy17\hr21\min33}{\version3}{\edmins21}{\nofpages3}{\nofwords1398}{\nofchars7972}{\*\company CHDR}{\nofcharsws0}{\vern8243}}\paperw11906\paperh16838 \widowctrl\ftnbj\aenddoc\noxlattoyen\expshrtn\noultrlspc\dntblnsbdb\nospaceforul\hyphcaps0\formshade\horzdoc\dghspace120\dgvspace120\dghorigin1701\dgvorigin1984\dghshow0\dgvshow3\jcompress\viewkind1\viewscale100\pgbrdrhead\pgbrdrfoot\nolnhtadjtbl \fet0 \sectd \linex0\headery709\footery709\colsx709\endnhere\sectdefaultcl {\*\pnseclvl1\pnucrm\pnstart1\pnindent720\pnhang{\pntxta .}}{\*\pnseclvl2\pnucltr\pnstart1\pnindent720\pnhang{\pntxta .}}{\*\pnseclvl3\pndec\pnstart1\pnindent720\pnhang{\pntxta .}} {\*\pnseclvl4\pnlcltr\pnstart1\pnindent720\pnhang{\pntxta )}}{\*\pnseclvl5\pndec\pnstart1\pnindent720\pnhang{\pntxtb (}{\pntxta )}}{\*\pnseclvl6\pnlcltr\pnstart1\pnindent720\pnhang{\pntxtb (}{\pntxta )}}{\*\pnseclvl7\pnlcrm\pnstart1\pnindent720\pnhang {\pntxtb (}{\pntxta )}}{\*\pnseclvl8\pnlcltr\pnstart1\pnindent720\pnhang{\pntxtb (}{\pntxta )}}{\*\pnseclvl9\pnlcrm\pnstart1\pnindent720\pnhang{\pntxtb (}{\pntxta )}}\pard\plain \s1\ql \li0\ri0\keepn\widctlpar\faauto\outlinelevel0\adjustright\rin0\lin0\itap0 \i\f28\fs20\lang2057\langfe1033\cgrid\langnp2057\langfenp1033 {\b\fs28 Submitting an abstract for the PAGE meeting \par }\pard\plain \ql \li0\ri0\widctlpar\faauto\adjustright\rin0\lin0\itap0 \fs20\lang2057\langfe1033\cgrid\langnp2057\langfenp1033 {\f28\fs17 \par Abstracts must be submitted online to the PAGE web site (www.page-meeting.org) by clicking on 'Register / submit abstract' under the heading for the upcoming meeting. You must register as a participant before yo u can submit an abstract and you can only register after you've provided us with your personal address information. Upon submission of an abstract, an e-mail will be sent out to you with your abstract and a pdf of the HTML-code. This e-mail will also be sent to the committee respons ible for peer review in the selected category and abstract-updates may be requested. Abstracts will remain invisible until release of the final program. \par }\pard \ql \li0\ri0\sb100\sa100\widctlpar\faauto\adjustright\rin0\lin0\itap0 {\f28\fs17 We strongly prefer a }{\f28\fs17\ul structured abstract}{\f28\fs17 (Objectives/Methods/Results/Conclusion/References) with number of characters (including spaces) }{ \f28\fs17\ul not exceeding 2,500 but not less than 1,000}{\f28\fs17 for the abstract itself (excluding Authors and References). An example is provided below. \par }\pard \ql \li0\ri0\widctlpar\faauto\adjustright\rin0\lin0\itap0 {\f28\fs17 There are separate fields for entering your abstract title, the authors, the associated institution or affiliation and the t ype of abstract you wish to present (oral or poster in different categories). If authors are from different institutions please use the following format: \par \par Title:\tab \tab Title Using Title Case \par Author: \tab \tab Author1 (1), Author2 (1), Author3 (2) \par Institution:\tab (1)Affiliation1; (2) Affiliation2 \par \par The abstract text itself must have the following layout: \par \par }{\b\f28\fs17 Objectives:}{\f28\fs17 Text regarding objectives. \par \par }{\b\f28\fs17 Methods:}{\f28\fs17 Text regarding methods. \par \par }{\b\f28\fs17 Results:}{\f28\fs17 Text regarding results. \par \par }{\b\f28\fs17 Conclusions:}{\f28\fs17 Text regarding conclusions. \par \par }{\b\f28\fs17 References: \par }{\f28\fs17 [1] Text for reference 1. \par [2] Text for reference 2, etc etc \par \par \par }\pard\plain \s1\ql \li0\ri0\keepn\widctlpar\faauto\outlinelevel0\adjustright\rin0\lin0\itap0 \i\f28\fs20\lang2057\langfe1033\cgrid\langnp2057\langfenp1033 {\b\fs28 How to produce such an abstract \par }\pard\plain \ql \li0\ri0\widctlpar\faauto\adjustright\rin0\lin0\itap0 \fs20\lang2057\langfe1033\cgrid\langnp2057\langfenp1033 {\f28\fs17 \par }\pard\plain \s2\ql \li0\ri0\keepn\widctlpar\faauto\outlinelevel1\adjustright\rin0\lin0\itap0 \b\i\f28\fs17\lang2057\langfe1033\cgrid\langnp2057\langfenp1033 {\b0\i0 There are two options for entering abstracts, depending on the type of internet-browser you use. \par }\pard\plain \ql \li0\ri0\widctlpar\faauto\adjustright\rin0\lin0\itap0 \fs20\lang2057\langfe1033\cgrid\langnp2057\langfenp1033 { \par }\pard\plain \s2\ql \li0\ri0\keepn\widctlpar\faauto\outlinelevel1\adjustright\rin0\lin0\itap0 \b\i\f28\fs17\lang2057\langfe1033\cgrid\langnp2057\langfenp1033 {Internet Explorer and MsWord \par }\pard\plain \ql \li0\ri0\widctlpar\faauto\adjustright\rin0\lin0\itap0 \fs20\lang2057\langfe1033\cgrid\langnp2057\langfenp1033 {\f28\fs17 Maximum ease is provided for users of Internet Explorer 5.5 and up. Al l you need to do is make your abstract in MsWord, choose select all (control A), copy it (control C) and then past it (control V) in the internet-abstract window. If you use symbols (like sigma), be sure to use the "normal text" font and not the "symbol" font, because it will not copy well. \par \par }\pard\plain \s2\ql \li0\ri0\keepn\widctlpar\faauto\outlinelevel1\adjustright\rin0\lin0\itap0 \b\i\f28\fs17\lang2057\langfe1033\cgrid\langnp2057\langfenp1033 {All other browsers \par }\pard\plain \ql \li0\ri0\widctlpar\faauto\adjustright\rin0\lin0\itap0 \fs20\lang2057\langfe1033\cgrid\langnp2057\langfenp1033 {\f28\fs17 If you do not use Internet Explorer, abstracts must be entered as plain text with formatting options applied using a restricted set of HTML-codes. \par \par Basically, the only HTML-codes allowed are: \par \par
and
: between these two codes, text is entered for a paragraph. Two paragraphs are automatically separated by a blank line. \par and : between these two codes, text is displayed as bold. \parObjectives: Text regarding objectives.
\parMethods: Text regarding methods.
\parResults: Text regarding results.
\parConclusions:
Text regarding conclusions.
References: [1] Text for reference 1.
\par [2] Text for reference 2, etc etc
Objectives: The reverse transcriptase inhibitor efavirenz i s currently used at a fixed dose of 600 mg qd. Dosage individualisation based on plasma concentration monitoring might however be indicated. This study aimed to assess efavirenz pharmacokinetic profile and interpatient versus intrapatient variability in H IV positive patients to explore the relationship between drug exposure, efficacy and CNS toxicity and to build up a Bayesian approach for dosage adaptation.
\parMethods: The population pharmacokinetic analysis was performed using NONMEM based on plasma samples from a cohort of unselected patients receiving efavirenz. With the use of a one-compartment model with first order absorption, the influence of demographic and clinical characteristics on oral clearance and oral volume of distribu t ion were examined. The average drug exposure over one dosing interval was estimated for each patient and correlated with markers of efficacy and toxicity. The population kinetic parameters and the variabilities were integrated into a Bayesian equation for dosage adaptation based on a single plasma sample.
\parResults: 235 patients contributed to 719 efavirenz concentrations. Oral clearance was 9.4 L/h, oral volume of distribution was 252 L and the absorption rate constant was 0.3 h-1. O f the covariates evaluated, the African ethnicity and drugs inhibiting the cytochrome P4503A4 showed an influence on efavirenz pharmacokinetics. A large interpatient variability was found to affect efavirenz relative bioavailability (CV 54.6%), while the i ntrapatient variability was small (CV 26%). An inverse correlation between average drug exposure and viral load and a trend with CNS toxicity were detected. This enabled the derivation of a dosing adaptation strategy suitable to bring the average concentr ation into a therapeutic target of 1000-4000 mg/L, to optimise viral load suppression and minimise CNS toxicity.
\parConclusion: The high interpatient and low intrapatient variability, along with the relationship with markers of efficac y and toxicity, make efavirenz a drug suitable for therapeutic drug monitoring. Individualisation of efavirenz dosage regimen based on routine drug level monitoring appears suitable for its optimal management.
\par }}